G4-PROTAC is designed for specific degradation of a G4-binding protein (RHAU/DHX36) which has been reported to be highly expressed in tissues of C9orf72-linked amyotrophic lateral sclerosis (ALS) patients and thus represents an important therapeutic target [138]. The gene discussed is C9orf72; the disease is amyotrophic lateral sclerosis.